Navigation Links
Appetite Changes, Depression Signal Impulse Control Disorders in Parkinson

Parkinson disease patients who develop impulse control disorders as a result of treatment are more likely to be depressed, irritable, and have appetite changes, according// to a study published in the October 10, 2006, issue of Neurology, the scientific journal of the American Academy of Neurology. These findings could allow early identification of patients at risk for developing this distressing complication of treatment.

Compulsive gambling, hypersexuality, and excessive shopping have been linked to treatment with dopamine agonists in small numbers of patients. It is unknown exactly how many patients experience such an impulse control disorder, although it is believed to be less than 10 percent of those receiving these drugs.

To identify risk factors for development of impulse control disorder, the authors studied 100 Parkinson disease patients, including 66 men and 34 women, who were receiving the full range of standard anti-Parkinson medications, including levodopa, dopamine agonists, and other drugs. They administered a standard battery of psychiatric tests to identify the presence of depression, anxiety, delusions, and other psychiatric conditions, as well as impulse control disorder.

They found that nine of the 100 patients had an impulse control disorder, including four with pathological gambling, two with hypersexuality, one with excessive shopping, and two with both hypersexuality and excessive shopping. All nine were receiving a dopamine agonist, in addition to other medications.

Compared to patients without an impulse control disorder, patients with one were more than twice as likely to have depressive symptoms, were more than three times as likely to have appetite changes, and were more than six times as likely to have symptoms of irritability and disinhibition.

“These results highlight the potential usefulness of depression and appetite changes as ‘sentinel symptoms’ associated with an impulse control disorder,” according to lead study author Laura Marsh, MD, with Johns Hopkins University School of Medicine in Baltimore, Maryland, and a member of the American Academy of Neurology. “Since only a small fraction of patients receiving dopamine agonists develop this disorder, these findings may help identify those most at risk. Strategies for treatment may include changing medications or avoiding situations that may lead to the impulsive behavior.”

Source-NewswiseSRM
'"/>




Related medicine news :

1. The Reason For Loss Of Appetite After Gastric Bypass
2. Stomach Hormone to Aid in Controlling Appetite
3. Study Highlights Appetite Regulation Pathway, New Hope for Weight Loss
4. Brain behind the Brawn: Vital Molecule in the Brain Controls Appetite
5. Study Confirms That Slow Eating Restricts Appetite
6. Estrogen Curbs Appetite: Research
7. Estrogen Curbs Appetite In Same Way as the Hormone Leptin
8. Mitochondrial Protein Maintains Appetite During Fasting
9. Role of Appetite Hormone MCH in Insulin Production Revealed
10. Low Cholesterol Linked to Severe Depression and Violent Behavior in Men
11. Depression may cause delayed wound healing
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/24/2017)... ... ... Millions of families and businesses worldwide depend on high quality water from ... water. However, well water can also become contaminated with bacteria and odors from flood ... The EPA does not regulate private drinking water wells. Many states and towns do ...
(Date:9/24/2017)... ... ... boy was walking home and feeling down about himself. He didn’t think he was good ... he can do whatever he wants to do if he puts his mind to it. ... God created him with special talents and gifts. We see his internal dialogue change. He ...
(Date:9/24/2017)... ... ... The Other Sheep”: the ceremonial laws of Moses and the Holy Law of God reexamined. ... author, Maurice Caines. Maurice Caines resides in the sunny isle of Florida, but he ... Adventist Church for many years. He was previously a member of the Anglican Church ...
(Date:9/23/2017)... San Francisco, CA (PRWEB) , ... September 23, 2017 , ... ... Bay Area, is proud to announce a new blog post focused on the ARTAS® ... loss, they understandably hope to turn to the latest, most technologically sophisticated methods of ...
(Date:9/22/2017)... Albert Lea, MN (PRWEB) , ... September 22, 2017 , ... ... and video) at its rally to interview citizens on why they are rallying against ... stories and commitment to this effort against Dr. Noseworthy’s (CEO) decision to close the ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... 2017  Eli Lilly and Company (NYSE: ... data for lasmiditan, an investigational, oral, first-in-class molecule for ... improvements compared to placebo in the Phase 3 SPARTAN ... 18th Congress of the International Headache Society (IHC) in ... presented today demonstrate lasmiditan,s potential to reduce pain and ...
(Date:9/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... will be participating in the Morgan Stanley 15 th ... hotel in New York.  Zimmer Biomet will present on ... A live webcast of the presentation can ... http://investor.zimmerbiomet.com .   ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
Breaking Medicine Technology: